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Enzyme-Assisted Antibiotic
Engineering—
the Wright Way
Wright and coworkers describe the design, synthesis,
and screening of cyclic peptides with chimeric struc-
tures that draw from two disparate antibiotics, tyroci-
dine and a type B streptogramin [1]. An active com-
pound identified appears to function by a different
mechanism of action than the parent antibiotics and
also overcomes resistance to type B streptogramins.
Metabolic engineering is frequently provided as an
ultimate goal behind natural product biosynthetic path-
way research. While considerable development has
been made both in academia and industry, it is clear
that polyketide and nonribosomal peptide synthase
engineering will require significant development before
it becomes widely used as a synthetic technique. Luck-
ily, natural product pathway elucidation also provides
the chemist with new tools for chemoenzymatic pro-
cesses [2]. Using enzymes with broad substrate speci-
ficity, chemists may capitalize upon the chemo-, regio-,
and stereospecificity of enzymatic catalysis. The selec-
tive choice of specificity provides further versatility to
synthetic chemistry. Wright and coworkers demon-
strate that enzymes may be used not merely as tools
for process chemistry, but they may also serve as ro-
bust catalysts for drug discovery.
Nonribosomal peptide synthases (NRPSs) produce a
diverse array of therapeutic molecules, including the
clinically important antibiotics penicillin, vancomycin,
bacitracin, gramicidin S, and streptogramin. Due to the
emergence of antibiotic-resistant bacterial strains and
the fact that natural product screens now return over
99% known compounds [3], a fusion of organic synthe-
sis, molecular engineering, and natural product chemis-
try is currently being called upon to fill a growing need
for new antibacterials. Mukhtar, Koteva, and Wright [1]
report a synthesis relying on all three disciplines. They
start with two antibiotics, one of which is semisyn-
thetic, and merge them using solid-phase peptide
chemistry and catalytic cyclization with the macrocy-
cle-forming thioesterase (TE) domain from Tyrocidine C
(TycC) biosynthesis. The use of TycC TE for chemoen-
zymatic synthesis on solid phase is by now well estab-
lished [4]. This enzyme has been used in the recent
past for the creation of small cyclic peptides (6–14
amino acids) and for the synthesis of peptide-polyke-
tide hybrids and glycopeptides [5–7].
Streptogramin antibiotics are classified either as type
A, cyclic peptide-polyketide macrolactones, or type B,
cyclic depsipeptides. Both classes act on the bacterial
ribosome, with type A binding the peptidyl transfer cen-
ter and type B blocking the peptide exit tunnel [1]. Type
A and B streptogramins also act synergistically, where
binding of a type A compound facilitates the binding ofrved. DOI 10.1016/j.chembiol.2005.01.010
a type B compound. Although known for over 50 years,
streptogramin antibiotics were only recently approved
for human use [8]. Synercid, introduced by Rhone-
Poulenc in 1999, is a mix of dalfopristin (type A) and
quinupristin (type B) streptogramins. Perhaps because
of their long use in agriculture, streptogramin B resis-
tance is already widely reported and occurs through
one of three mechanisms: efflux by Msr pumps, methyl-
ation of 23S rRNA by Erm, or cleavage of the cyclic
ester by Vgb. The authors reason that, if the vulnerable
ester in type B streptogramins were replaced with a
more stable amide linkage, the new compound would
be impervious to the lyase action of Vgb. They develop
a strategy using chemoenzymatic synthesis to create a
chimeric antibiotic. In so doing, the depsipeptide ester
is replaced by an amide using solid phase peptide syn-
thesis and the TycC TE enzyme as a catalyst. This en-
zyme has been shown to be promiscuous in cyclizing
a number of small peptides when the first amino acid
contains an aromatic ring and the penultimate residue
contains a cationic amino functionality [4]. Using this
approach, the authors create a collection of com-
pounds containing both the active portions of quinpris-
tin (a type B streptogramin) and the moieties of tyroci-
dine required for cyclization. By preserving biologically
active portions of both starting compounds, the au-
thors propose a rational approach to design chimeric
antibiotics.
These studies identified several compounds demon-
strating antimicrobial activity without susceptibility to
Vgb hydrolysis. The authors chose one top candidate
for further characterization (compound 5) and report
that it demonstrates an MIC range from 32 to 256 g/ml
against gram-positive bacteria. Most surprisingly, the
compound seems to act through an unusual mecha-
nism of action. Compound 5 is neither a substrate for
Vgb nor an inhibitor of it—evidence that the conserved
ester in type B streptogramins is required for Vgb bind-
ing. This information alone may prove useful for future
attempts to design streptogramin analogs. The mole-
cule was not synergistic with dalfopristin (a type A
streptogramin), nor did it interact with the ribosome. In
addition, the compound was not active in disrupting
membranes, which is the mode of action for tyrocidine.
Taken together, these results are quite remarkable: the
authors have created a chimeric antibiotic that over-
comes known resistance mechanisms and appears to
have a mode of action separate from its parent com-
pounds.
This report illustrates the advantages in combining
organic synthesis with natural product biosynthetic en-
zymes to further drug discovery. While the authors call
this serendipity, it is more likely a case of chance favor-
ing the prepared mind. Nature has spent millions of
years evolving active motifs into natural products, so it
is perhaps not surprising that, by retaining the active
portions of the two natural products, a new—or pre-
viously undiscovered—biological interaction was un-
covered. This idea would follow the discovery by Kahne
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monstrate dual activities inhibiting separate peptido- 1
glycan biosynthetic enzymes at opposite sites of the
molecule [9]. 2
This work also raises the prospect of creating a li-
brary of TE domains as a toolkit for molecular discov-
3ery. What sort of previously undiscovered reactions and
molecules would then be available? And if a molecule is
discovered in this way and proves to be a useful clinical
agent, could large-scale production of these peptides 4
be achieved? We turn again to the prospect of meta-
5bolic engineering, which may be the method by which
to produce compound 5 on a process scale.
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